Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

Scientific Reports
Kai-Che WeiPing-Chin Lai

Abstract

Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database. Patients who had rituximab-based chemotherapy were included in the experimental (rituximab) group, while the rest of the patients who did not receive any rituximab-based chemotherapy throughout the study period formed the control group. The prevalence rate of pneumocystis infection in the rituximab group (N = 7,554) was significantly higher than that in the control group (N = 4,604) (2.95% vs. 1.32%). The onset of pneumocystis infection occurred between 6 and 16 weeks after chemotherapy. Patients who had pneumocystis prophylaxis, whether or not they had a pneumocystis infection later in their treatment course, had signi...Continue Reading

References

Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Frances E LundBeth A Garvy
Nov 4, 2004·Journal of the American Academy of Dermatology·Lynne H Morrison
Aug 4, 2005·Cancer·Roy F ChemalyIssam I Raad
Apr 28, 2006·Clinical Lymphoma & Myeloma·Harrys A TorresRoy F Chemaly
Jan 30, 2008·The Lancet Oncology·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Apr 15, 2008·International Journal of Hematology·Daisuke EnnishiKiyohiko Hatake
Jan 28, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S I MartinUNKNOWN AST Infectious Diseases Community of Practice
Jun 29, 2010·Arthritis Care & Research·Boris HugleSusanne Benseler
Jan 18, 2012·Cancer Immunology, Immunotherapy : CII·Dina StroopinskyIrit Avivi
Oct 16, 2012·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ming-Chi LiWen-Chien Ko
Dec 22, 2012·Chest·Isabel Martin-GarridoAndrew H Limper
Jan 25, 2014·Transplant Infectious Disease : an Official Journal of the Transplantation Society·L Perez-OrdoñoC Cervera
Mar 4, 2015·Infection and Immunity·Waleed ElsegeinyJay K Kolls
Aug 24, 2016·The Journal of Antimicrobial Chemotherapy·Johan MaertensUNKNOWN 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Tran

❮ Previous
Next ❯

Citations

Mar 4, 2020·Journal of Fungi·Camila BonicheCarlos Pelleschi Taborda
Apr 11, 2019·Nature Reviews. Rheumatology·Samuel J S RubinWilliam H Robinson
Jul 12, 2019·Frontiers in Immunology·Dario DidonaMichael Hertl
Apr 20, 2021·Expert Opinion on Pharmacotherapy·R Benson WeyantCarlos Cervera
Aug 3, 2021·Current Clinical Microbiology Reports·Marilia Bernardes, Tobias M Hohl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved